Advertisement
Advertisement
KYMR
Kymera Therapeutics, Inc. Common Stock
113.37
USDSponsored
+2.31
+2.08%
Jul 21, 16:00 UTC -4
Closed
After-Market
113.36
-0.01
0.00%
KYMR Earnings Reports
Positive Surprise Ratio
KYMR beat 7 of 23 last estimates.
30%
Next Report
Date of Next Report
Jul 31, 2026
Estimate for Q2 26 (Revenue/ EPS)
$29.97M
/-$0.74
Implied change from Q1 26 (Revenue/ EPS)
-12.78%
/+4.23%
Implied change from Q2 25 (Revenue/ EPS)
+161.17%
/-22.11%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On Apr 30, 2026, KYMR reported earnings of -0.71 USD per share (EPS) for Q1 26, beating the estimate of -0.89 USD, resulting in a 21.05% surprise. Revenue reached 34.37 million, compared to an expected 8.79 million, with a 291.12% difference. The market reacted with a -0.54% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.74 USD, with revenue projected to reach 29.97 million USD, implying an increase of 4.23% EPS, and decrease of -12.78% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jul 09, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.81
Surprise
-10.78%
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.71, beating estimates by 21.05%, and revenue of $34.37M, 291.12% above expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.54%, changed from $81.51 before the earnings release to $81.07 the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jul 31, 2026.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 13
analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.74 and revenue of $29.97M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement